<DOC>
	<DOCNO>NCT00300521</DOCNO>
	<brief_summary>Previous rather poor result liver transplantation ( LT ) patient advance hepatocellular carcinoma ( HCC ) make application LT limit treatment HCC . The advantage ADV-TK gene therapy highlight potentiality adjuvant treatment HCC patient LT. We report improved outcome LT combine treatment ADV-TK gene therapy patient intermediate advanced HCC .</brief_summary>
	<brief_title>Liver Transplantation With ADV-TK Gene Therapy Improves Survival Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>The overall survival LT ADV-TK gene therapy group 54.8 % three year , recurrence-free survival group 56.5 % , high transplantation group ( P=0.0001 overall survival P=0.0000 recurrence-free survival ) . In no-vascular invasion subgroup treat LT ADV-TK therapy , overall survival recurrence-free survival 100 % , significantly high vascular invasion subgroup treat combined LT ADV-TK therapy ( P=0 group ) . Vascular invasion important factor affect survival recurrence , hazard ratio=3.687 ; P=0.014 hazard ratio=12.961 ; P=0.000 , respectively .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Clinical diagnosis advance hepatocellular carcinoma metastasis lung bone Accept Liver Transplantation Small hepatocellular carcinoma Advanced hepatocellular metastasis lung bone</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2000</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>liver transplantation</keyword>
	<keyword>adenovirus-thymidine kinase enzyme</keyword>
	<keyword>gene therapy</keyword>
	<keyword>immunosuppression</keyword>
</DOC>